Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues
Year: 2014
Type: article
Study design: Observational Study
Abstract: The ability to target myeloid malignancies using immunotherapy through means other than allogeneic transplantation depends on the capability to target leukemic clones while sparing normal tissues. It is now possible to generate clinical grade ex-vivo expanded T cells specific for leukemia-associated antigens (LAAs) for use in adoptive cell therapy. 1 Although a variety of putative LAAs in acute myeloid leukemia (AML) have been identified for use as potential targets for immunotherapy 2 , 3 , 4 , 5 , 6 , 7 , 8 and consensus panels have attempted to prioritize generic cancer antigens, 9 a comprehensive evidence-based list of AML antigen targets has not yet been established. As a first step toward this goal, we therefore analyzed, using quantitative real-time PCR, the gene expression of 65 potential LAAs ( Supplementary Table S1 ) in de-identified, clinically annotated samples from 48 newly diagnosed untreated AML patients that were collected under institutional review board-approved protocols from three NCCN cancer centers.
Source: Leukemia
DOI: 10.1038/leu.2014.14
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Johns Hopkins University, European Commission, Warszawski Uniwersytet Medyczny, Uniwersytet Warszawski, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Advancing Translational Sciences, FP7 Research Potential of Convergence Regions
OpenAlex ID: W2105399717